Long- Term Transcranial Direct Current Stimulation in Parkinson's Disease

Long-Term Transcranial Direct Current Stimulation in Parkinson's Disease

The goal of the proposed research is to determine the influence of transcranial direct current stimulation (tDCS) on long-term motor learning, transfer of motor learning, and cortical function in Parkinson's disease (PD). The project comprises a 2 week training study that will involve tDCS applied during two practice motor tasks with behavioral, clinical, and physiological evaluations at baseline as well as 1, 14 and 28 days following the 2 week training and stimulation period. The findings of the proposed studies should have significant clinical significance and applications to comprehensive intervention therapy development in the treatment of PD.

Study Overview

• Status: Unknown
• Conditions: Parkinson Disease
• Intervention / Treatment: Device: Anodal tDCS; Device: SHAM tDCS

Detailed Description

Parkinson's disease (PD) is the second most common neurodegenerative disorder and affects approximately 1 million people in the United States with total annual costs approaching 11 billion dollars. Current medical and surgical treatment approaches for PD are either only mildly effective, expensive, or associated with a variety of side effects. Therefore, the development of practical and effective therapeutic adjuncts to current treatment approaches would have significant benefits.

Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation technique that can modulate cortical excitability and improve motor function in healthy subjects, older adults, and in stroke. However, there are several crucial issues that currently prevents the determination of the viability of tDCS as an adjunct intervention in PD. For example, the magnitude to which tDCS may be able to improve long-term motor learning beyond what can be achieved by practice alone in PD is unknown. It is also unclear if short-term improvements in motor function induced by tDCS and measured in the OFF state in PD can be attained over the long-term in the ON state, which is necessary for real world application. In addition, it is uncertain if the effects of tDCS generalize to non-practiced tasks and to the ipsilateral, non-tDCS stimulated hand. Finally, the physiological mechanisms underlying any of these issues have not been identified because no long-term motor learning tDCS studies in PD to date have concurrently quantified behavioral, clinical, and physiological measures.

The project will be a single-center, double-blind, randomized, sham-controlled, experimental design. PD patients will practice 2 motor tasks (practice tasks) with their right (primarily affected) hand in 9 practice sessions over a 2 week period in association with either tDCS or SHAM stimulation of the left (contralateral) motor cortex. In addition, 4 testing sessions will be performed and will include a Baseline test, an end of training test (EOT), a follow up test 2 weeks after the end of training (EOT+14), and a follow up test 4 weeks after the end of training (EOT+28). The primary outcome variables will be the force error in the first practice task (precision grip task; PGT) and the stroke amplitude, stroke variability, and writing speed in the second practice task (handwriting task; HWT). The secondary outcome variables the Unified Parkinson's Disease Rating Scale (UPDRS) Part 3, the Purdue Pegboard Test (PT), and the Jebsen Taylor Hand Function Test (JTT).

• Study Type: Interventional
• Enrollment (Anticipated): 40
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Nevada
    • Las Vegas, Nevada, United States, 89154-3034
      • Bigelow Health Sciences

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 60 years to 75 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Able to provide informed consent.
2. A clinical diagnosis of idiopathic PD.
3. A stable and optimal medical regimen of anti-parkinsonian drug therapy for the duration of the study.
4. Modified Hoehn and Yahr stage between 1.0 and 3.0 in the OFF state.
5. Right-hand dominant and primarily right-side affected to prevent confounds due to handedness and affected side.

Exclusion Criteria:

1. An uncontrolled medical condition (i.e. hypertension, diabetes, etc).

2. Evidence of secondary or atypical parkinsonism as suggested by:

   1. History of CVA's, exposure to toxins, neuroleptics or encephalitis.
   2. Neurologic signs of upper motor neuron or cerebellar involvement, supranuclear gaze palsy or significant orthostatic hypertension.
3. Metal in the skull or the eye, such as a cardiac pacemaker, brain stimulator, shrapnel, surgical metal, clips in the brain, cochlear implants, and metal fragments in the eye, as these may make TMS and tDCS unsafe.
4. An uncertainty about the presence of metal objects in a subject's body exists.
5. Hearing loss, have had a brain tumor, a stroke, head trauma, epilepsy or a history of seizures, have another neurological disorder other than a movement disorder, or have a head injury where they passed out for more than a few seconds.
6. Pregnant or thought to be pregnant.
7. Irrepressible dyskinesia or tremor to prevent the confound of excessive EMG during TMS testing at rest.
8. Any other neurological disorders.
9. Meeting of any of the TMS exclusion criteria given in international guidelines.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: QUADRUPLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Anodal tDCS; Anodal tDCS will be applied in nine experimental sessions over a 2-week period.	Device: Anodal tDCS; Anodal tDCS will be applied over the FDI muscle representational area of the motor cortex for 25 minutes in combination with the two motor tasks (precision grip task and handwriting task).
SHAM_COMPARATOR: SHAM tDCS; SHAM tDCS will be applied in nine experimental sessions over a 2-week period.	Device: SHAM tDCS; SHAM tDCS will be applied over the FDI muscle representational area of the motor cortex for 25 minutes in combination with the two motor tasks (precision grip task and handwriting task).

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Force error in the precision grip task	Changes in force error after the two week intervention	Baseline, 1 day post, 2 weeks post, 4 weeks post
Handwriting task performance	Changes in stroke amplitude, stroke variability, and writing speed after the two week intervention	Baseline, 1 day post, 2 weeks post, 4 weeks post

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Transfer of motor learning	Changes in the UPDRS Motor Section Part 3 after the two week intervention	Baseline, 1 day post, 2 weeks post, 4 weeks post
Transfer of motor learning	Changes in the Purdue Pegboard Test after the two week intervention	Baseline, 1 day post, 2 weeks post, 4 weeks post
Transfer of motor learning	Changes in the Jebsen Taylor Hand Function Test after the two week intervention	Baseline, 1 day post, 2 weeks post, 4 weeks post

Collaborators and Investigators

• Sponsor: University of Nevada, Las Vegas
• Investigators: Principal Investigator: Brach Poston, Ph.D., University of Nevada, Las Vegas

Study record dates

Study Major Dates

• Study Start (ACTUAL): July 30, 2018
• Primary Completion (ANTICIPATED): June 30, 2020
• Study Completion (ANTICIPATED): December 31, 2020

Study Registration Dates

• First Submitted: August 16, 2018
• First Submitted That Met QC Criteria: August 16, 2018
• First Posted (ACTUAL): August 20, 2018

Study Record Updates

• Last Update Posted (ACTUAL): October 19, 2018
• Last Update Submitted That Met QC Criteria: October 18, 2018
• Last Verified: October 1, 2018

More Information

Terms related to this study

• Keywords: tDCS; motor learning; motor cortex; handwriting; cortical excitability; micrographia
• Additional Relevant MeSH Terms: Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Parkinsonian Disorders; Basal Ganglia Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases; Parkinson Disease
• Other Study ID Numbers: 1002548

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No